Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kevin Main

Physician Assistant, Medical Gilbert, AZ Physician Assistant

NPI 1194126425 CMS profile 10560208

3303 E Baseline Rd Ste 208, Gilbert, AZ 85234

Open in the dashboard

General payments

$15,692

728 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Main of Gilbert, AZ is reported in the CMS Open Payments database as having received $15,692 across 728 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,817 185
2024 General $3,179 137
2023 General $2,981 145
2022 General $2,877 148
2021 General $1,839 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Main
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kevin Main were reported at $4,817. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kevin Main Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,839 $156 $41–$563 $132
2022 $2,877 $185 $55–$649 $149
2023 $2,981 $199 $58–$717 $160
2024 $3,179 $206 $62–$740 $164
2025 $4,817 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,128 94 payments
  2. GlaxoSmithKline, LLC. $1,438 90 payments
  3. Genzyme Corporation $1,252 63 payments
  4. Regeneron Healthcare Solutions, Inc. $1,170 52 payments
  5. Inspire Medical Systems, Inc. $1,112 17 payments
  6. Mylan Specialty L.P. $690 37 payments
  7. Actelion Pharmaceuticals US, Inc. $663 23 payments
  8. Jazz Pharmaceuticals Inc. $633 27 payments
  9. Amgen Inc. $552 29 payments
  10. Grifols USA, LLC $537 27 payments
  11. Other $5,517 269 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,621 717 payments
  2. Travel and Lodging $827 4 payments
  3. Education $244 7 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,422 66 payments
  2. FASENRA $1,116 32 payments
  3. INSPIRE $1,112 17 payments
  4. BREZTRI $1,021 38 payments
  5. DUPIXENT Inflammation And Immunology $891 42 payments
  6. YUPELRI $855 47 payments
  7. AIRSUPRA $852 19 payments
  8. TRELEGY ELLIPTA $720 45 payments
  9. NUCALA $687 42 payments
  10. OPSUMIT $639 22 payments
  11. Other $9,941 460 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,384

Median for Physician Assistant: 241

Drug cost

$556,511

Median for Physician Assistant: $4,110

Branded share of claims

65.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 216 $248,011
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 137 $120,108
Pirfenidone Generic 11 $51,507
Breo Ellipta Fluticasone/Vilanterol Brand 64 $34,227
Spiriva Respimat Tiotropium Bromide Brand 22 $15,469
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 13 $14,017
Eliquis Apixaban Brand 11 $12,521
Arnuity Ellipta Fluticasone Furoate Brand 35 $12,201
Symbicort Budesonide/Formoterol Fumarate Brand 26 $8,834
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 53 $8,499

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$687 — —
OPSUMIT
$231 — —
YUPELRI
$189 — —
TEZSPIRE
$187 — —
NUCALA
$174 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

728 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record